Evidence map›Paper›PMID 39205319›Full record

Observational studyViruses2024

Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study.

Dimitrios Basoulis, Elpida Mastrogianni, Georgios Karamanakos, Aikaterini Gkoufa, Vasiliki E Georgakopoulou, Sotiria Makrodimitri, Maria N Gamaletsou, Antonios Markogiannakis, Nikolaos V Sipsas

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dimitrios BasoulisInfectious Diseases Unit, Pathophysiology Department, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens Laiko, 11527 Athens, Greece.ORCID 0000-0002-0686-872X
Elpida MastrogianniEmergency Department, General Hospital of Athens Laiko, 11527 Athens, Greece.
Georgios KaramanakosFirst Propaedeutic Internal Medicine Department, General Hospital of Athens Laiko, 11527 Athens, Greece.ORCID 0000-0002-8870-6475
Aikaterini GkoufaInfectious Diseases Unit, Pathophysiology Department, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens Laiko, 11527 Athens, Greece.ORCID 0000-0001-5644-8208
Vasiliki E GeorgakopoulouInfectious Diseases Unit, Pathophysiology Department, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens Laiko, 11527 Athens, Greece.ORCID 0000-0003-0772-811X
Sotiria MakrodimitriInfectious Diseases Unit, Pathophysiology Department, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens Laiko, 11527 Athens, Greece.
Maria N GamaletsouInfectious Diseases Unit, Pathophysiology Department, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens Laiko, 11527 Athens, Greece.ORCID 0000-0002-0530-3209
Antonios MarkogiannakisPharmacy, General Hospital of Athens Laiko, 11527 Athens, Greece.
Nikolaos V SipsasInfectious Diseases Unit, Pathophysiology Department, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens Laiko, 11527 Athens, Greece.ORCID 0000-0001-6955-3453

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 continues to pose a threat to immunocompromised individuals, even with vaccination. The monoclonal antibodies (mAbs) tixagevimab/cilgavimab (TXG/CIL) provide targeted prophylaxis against SARS-CoV-2 with the benefit of a prolonged half-life. Although approved for COVID-19 prevention, there is limited data on their effectiveness among heavily immunocompromised populations.

methodsWe conducted a prospective, observational study at Laiko General Hospital, Athens, Greece, from August to December 2022 to investigate the efficacy of TXG/CIL as a form of pre-exposure prophylaxis in immunocompromised patients. Data on breakthrough SARS-CoV-2 infections were collected over a six-month follow-up period.

resultsOf the 375 participants (mean age 61.3 ± 14.1 years; 59.7% male), 76 (20.3%) developed breakthrough SARS-CoV-2 infections, with an incidence of 3.81 cases/100 patient months. Hospitalization was required for 21 patients (5.6%), with a median stay of 14 days. Seven deaths were recorded, with only one attributed to COVID-19. Previous infection (OR 0.46, 95% CI 0.26-0.82) and hybrid immunity (OR 0.52, 95% CI 0.29-0.92) can protect against new infection. Solid organ malignancy significantly increased the risk of severe outcomes among those infected (OR 7.4, 95% CI 2.2-24.7,

conclusionsTXG/CIL provides effective prophylaxis against COVID-19 in immunocompromised patients. Future strategies should focus on developing new mAb combinations to address emerging SARS-CoV-2 variants and protect vulnerable populations.

Indexed as

COVID-19Immunocompromised HostPre-Exposure ProphylaxisSARS-CoV-2AdultAgedAntibodies, Monoclonal, HumanizedFemaleGreeceHumansMaleMiddle AgedProspective StudiesAntibodies, Monoclonal, HumanizedCOVID-19immunocompromised patientsmonoclonal antibodiestixagevimab/cilgavimab

Identifiers

PMID39205319
PMCPMC11359519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.